News · Abbott Laboratories (ABT) · Healthcare

Abbott Laboratories rises 1.6% as TECTONIC trial posts positive 30-day outcomes

Session of October 30, 2026 · Published November 2, 2026 · 4 min read

What happened

Abbott (ABT) rose 1.6% on October 30, 2026, as reports said the TECTONIC trial posted positive 30-day outcomes and high procedural success for the investigational SonicForce™ Coronary Intravascular Lithotripsy system, according to GuruFocus and PRNewsWire. The company’s market value stood at $183.77 billion, and the stock closed at $106.20. The same day the S&P 500 fell 1.8% and the healthcare sector median fell 2.3%, placing Abbott’s performance 3.9 percentage points better than the sector median.

Closing price over the last 30 trading sessions. On October 30, 2026, ABT closed at $106.20, up 1.6% on the day and 3.1% higher than 30 sessions earlier.

How big was the move

Market participants treated the session as routine rather than extreme. The stock’s move was 1.2 times a typical daily move for this stock, a sizing that classifies it as an ordinary session. Trading volume ran at 0.8 times its 20-day average. Over the last five sessions the stock rose 2.4%, while the S&P 500 over five sessions fell 0.6%, reinforcing that Abbott outperformed the broader market in the short run.

Each bar is one day's price change; the outlined bar is October 30, 2026. A typical daily move over the past year was 1.7%, so the latest move equals 0.9 times that. Moves outside the dashed lines (about 3.4%) are unusual.

Abbott’s market sensitivity is low. A beta of 0.09 indicates the stock tends to move less than the market, and that muted sensitivity likely limited any headline-driven swings on the day.

The technical picture

Technically, the stock traded above its short- and long-term averages: it was 3.8% above its 20-day moving average, 1.8% above its 50-day moving average and 4.4% above its 200-day moving average. The 50-day average sat above the 200-day average, a sign of an established uptrend, and the stock had been above the 200-day average for 7 consecutive trading days.

Closing price over the past year. ABT ends the period 18.7% below its 52-week high, above its 50-day average ($104.34) and above its 200-day average ($101.69).

Momentum measures were neutral. The Relative Strength Index (14 days) was 60, inside a neutral range between 30 and 70. The stock remained 19.6% below its 52-week high. Time horizons diverged: over one month the stock rose 9.8%, over three months it fell 0.9% and over one year it fell 14.7%, which left it 24.7 percentage points behind the S&P 500. Volatility, measured as 21% annualized over 60 days, sat lower than 53% of its own readings over five years, indicating below-average recent turbulence.

Fundamentals and valuation

On a trailing four-quarter basis through September 30, 2026, Abbott reported revenue of $48.23 billion, which grew 10.0% from a year earlier and accelerated from revenue growth of 8.1% one quarter earlier. Diluted earnings per share were $2.70, while earnings per share growth from a year earlier fell 66.2%. Gross margin improved to 57.1% from 54.0% a year earlier, but operating margin narrowed to 15.2% from 17.8%.

Quarterly revenue by period end. The latest quarter brought $13.0B, 14.5% more than the same quarter a year earlier.

Return on invested capital was 5.6%, and the company reduced its share count by 0.6% over one year. Those figures point to solid top-line gains alongside pressure on near-term profitability and modest returns on capital.

Valuation contrasts with the fundamentals. Price to trailing earnings stood at 39.3 times trailing earnings, the highest reading of the past five years, against a five-year median of 30.1 times earnings. Price to forward earnings was 19.2 times expected earnings. Within PromtFinance scores, Quality ranked 94 (Exceptional) and Stability ranked 100 (Exceptional); Growth scored 34 (Weak) and Revisions scored 14 (Very weak). The combination suggests investors price Abbott for durable, high-quality characteristics while expecting slower near-term earnings momentum.

Earnings and analyst expectations

Abbott last reported on October 21, 2026, with earnings per share of $1.42 against $1.42 expected, matching estimates exactly. The company has 0 consecutive quarters beating estimates and an average surprise over the last four reports of 0.8% above estimates. The typical two-day reaction after recent reports was that the stock fell 1.9%.

Diluted earnings per share by quarter. The latest quarter shows $0.53, against $0.94 in the same quarter a year earlier.

Analysts remain generally positive. Forty-three analysts covered the company, with a consensus rating of Buy and 79% of ratings at Buy or Strong Buy. The consensus price target was $121.36, which is 14.3% above the closing price of $106.20. The next scheduled report is January 28, 2027.

For investors, the immediate interplay is clear: recent clinical news supplied a directional boost during a down day for the market, but valuation and earnings trends temper the case for a sustained re-rating. Revenue growth accelerated, yet earnings fell materially year over year and revisions scored very weak, factors that could limit upside absent clearer signs of margin recovery or sustained positive earnings revisions.

What to watch

January 28, 2027: next scheduled earnings report.
TECTONIC trial 30-day outcomes and high procedural success reported by GuruFocus and PRNewsWire; product is the SonicForce™ Coronary Intravascular Lithotripsy system.
Valuation at 39.3 times trailing earnings, the highest reading of the past five years.
One-year EPS change: earnings per share growth fell 66.2% for the four quarters through September 30, 2026.

Full ABT analysis: scores, chart and financials →